Published online Aug 15, 2015. doi: 10.4251/wjgo.v7.i8.102
Peer-review started: March 13, 2015
First decision: April 13, 2015
Revised: May 8, 2015
Accepted: July 11, 2015
Article in press: July 14, 2015
Published online: August 15, 2015
Processing time: 156 Days and 22.4 Hours
Currently, there is no international consensus on the best treatment regimen for patients with advanced resectable gastric carcinoma. In the United States, where a limited lymph-node dissection is frequently performed, adjuvant chemoradiotherapy after surgery is the standard treatment. In Europe, intensified perioperative chemotherapy is commonly administered. In Japan and South Korea, postoperative S-1-based adjuvant chemotherapy after surgery with D2 lymph-node dissection is the standard treatment. Several ongoing trials are currently evaluating the optimal sequence of chemotherapy, radiotherapy, and surgery, as well as the place of targeted therapeutic agents in the treatment of advanced gastric carcinoma.
Core tip: Gastric cancer (GC) treatment is controversy, particularly between Asia and Western countries. In this paper, we have performed a systematic and up-to-date review of resectable GC treatment strategies and discussed different treatment options. We have also discribed ongoing clinical randomized phase 3 trials and future directions in GC treatment.